Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

Publication date: Jan 20, 2020

The current first-line treatment for Opioid Use Disorder (OUD) in Canada is buprenorphine/naloxone (Suboxone). The standard induction method of buprenorphine/naloxone requires patients to be abstinent from opioids and thereby experience withdrawal symptoms prior to induction, which can be a major barrier in starting treatment. Rapid micro-induction (micro-dosing) involves the administration of small, frequent does of buprenorphine/naloxone and removes the need for a period of withdrawal prior to the start of treatment. This study aims to compare the effectiveness and safety of rapid micro-induction versus standard induction of buprenorphine/naloxone in patients with OUD.

Concepts Keywords
Agonist RTT
Allergy Analgesics
Anticipation Drugs
British Columbia Opioids
Buprenorphine Withdrawal symptoms
Canada Allergy
Clinical Trial Morphinans
Contraindicated Euphoriants
Hydromorphone Drug rehabilitation
Informed Consent Opioid antagonists
Interact Buprenorphine
Methadone Naloxone
Monograph Methadone
Naloxone Hydromorphone
Pregnancy Test
Urine Test
Withdrawal Symptoms


Type Source Name
drug DRUGBANK Buprenorphine
drug DRUGBANK Naloxone
disease MESH withdrawal symptoms
disease MESH Mental Disorders
disease MESH Diagnosis
drug DRUGBANK Hydromorphone
drug DRUGBANK Methadone
disease MESH allergy
disease MESH Substance-Related Disorders


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *